Canadian Phase Onward Inc.

Canadian Phase Onward Inc. (CPO) was opened in 2004 due to the growing interest from pharmaceutical companies in more non-hospital based Canadian sites to participate in their diverse clinical trials. CPO conducts Phase 2, 3 and 4 clinical research trials in a wide range of all diagnostic areas including but not limited to smoking cessation, diabetes, erectile dysfunction, hypertension, cardiovascular (general), migraine, weight loss, GERD, irritable bowel syndrome, constipation, diabetic peripheral neuropathy, metabolic syndrome, insomnia, pain relief, fibromyalgia, COPD, asthma,  schizophrenia, and depression. CPO also has experience in vaccine studies.

CPO is located at the same site, and operates in tandem with, the Polyclinic Family and Specialty Medicine Facility, resulting in a referral network of more than 60 specialists and 15 family physicians. CPO also has access to numerous medical and procedural testing facilities that are all available on-site, including phlebotomy, ECG, x-ray, ultrasound, bone density, mammography, gastroscopy and colonoscopy, full pulmonary function testing (including methacholine challenge testing), stress testing, echocardiography, stress-echocardiography, ambulatory blood pressure monitoring, holter monitoring, duplex dopler examination, audiology testing,  optometry, and a sleep laboratory.

CPO is located at 2 Champagne Drive (Champagne Centre), Unit A3, Toronto, ON M3J 0K2.

For inquiries, please contact us at 416-645-1783 or

Innovaderm Research Inc.

Innovaderm Research Inc. is a Clinical Research Organization specialized in Dermatology. The unique service offered by Innovaderm combines specialized Contract Research Services, scientific guidance, knowledge of dermatology sites in North America and the extended capabilities of a large clinical research site.

Syreon Corporation

Syreon is a leading technology-driven Contract Research Organization (CRO) combining elite biomedical sciences, advanced information technologies and global clinical trial networks to speed the evaluation of new drugs, diagnostics and medical devices and guide safe, effective and cost-efficient clinical use.